analysis
Dollar Reboot Review: Is Ian King's Strategic Fortunes Worth It?
Ian King's Dollar Reboot presentation says Elon Musk's xMoney stablecoin platform could reboot the dollar, with three small suppliers behind it. We vet the claims.
Reveal
Independent · Automated · Skeptical
We Read the Fine Print
So You Don't Have To.
NewsletterVetter detects new financial newsletter promos, extracts the full transcripts, reveals the "secret" stock picks, and vets every claim — hook, compliance, free tickers, and all. No hype. No upsell. Just the fine print, decoded.
Latest Vetted Promos
All vets →analysisXOVR
The Next Elon Musk Review: Is Matt Milner's Grey Swan Fraternity Worth It?
Matt Milner's Next Elon Musk presentation names Palmer Luckey's Anduril and hands over XOVR, a $50 ETF holding Anduril, free. We vet the 10x supplier thesis.
analysis
REB Infinite Power Review: Is Jon Najarian's Market Rebel Report Worth It?
Jon Najarian's Infinite Power presentation ties a $6 billion Houston company to xAI's Memphis power bypass. We checked the grid facts and the 'power as a service' thesis.
HIMS Hers Stock: What You Need to Know
hims hers stock explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
HIMS
Obesity Drug Companies: What You Need to Know
obesity drug companies explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
Obesity Drug Stocks: What Investors Need to Know
obesity drug stocks explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
Obesity Stocks: What You Need to Know
obesity stocks explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
Oral GLP-1: What Investors Need to Know
oral glp-1 explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
Retatrutide: What Investors Need to Know
retatrutide explained: what it means for investors and how The Motley Fool's research at The Motley Fool approaches this opportunity.
LLY
The Pipeline
How It Works
Every promo goes through the same five-step vet. No shortcuts, no "trust me." Each stage produces evidence you can read yourself.
Detect
We watch publisher sites, YouTube, and email inboxes for new promotional campaigns — automatically, 24/7.
Extract
Full transcript pulled from the VSL, including the disclaimer text most people scroll past.
Analyze
We break down the hook, the claims, the "free tickers," and the compliance disclosures.
Reveal
We name the "secret" stock the promo is teasing — usually deducible from public clues, not hidden.
Vet
We rate the whole thing: inflated, identifiable, recycled, or, occasionally, legitimate.
Most-Vetted Publishers
All publishers →The Oxford Club
185 vetsLong-running investment research publisher. Income, "beat the market" and longevity framings.
Brownstone Research
143 vetsFounded by Jeff Brown. Tech and biotech-focused promos; "near future" and "mega-trend" framing.
Paradigm Press
139 vetsAggressive crypto and "great wealth transfer" promos. Heavy use of urgency countdown framing.
Stansberry Research
113 vetsPorter Stansberry shop. Long-form VSLs, "end of America" macro narrative, gold/insurance teasers.
Banyan Hill
85 vetsLegacy independent publisher. Options, income, and "sovereign" framing.
InvestorPlace
51 vetsOne of the largest independent financial newsletter publishers. Aggressive promo cadence, frequent "free ticker" teasers.
The Motley Fool
26 vetsStock advisor services with frequent teaser campaigns around "stock split" or "next Apple" framings.
Angel Publishing
21 vetsSmall-cap and resource newsletter publisher; speculative "tiny company" framings.
Latest Articles
All articles →Oct 30, 2026
Ascendis Pharma Stock: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Eli Lilly Stock: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
GLP-1 Stocks: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
HIMS Hers Stock: What You Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Obesity Drug Companies: What You Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Obesity Drug Stocks: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Obesity Stocks: What You Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Oral GLP-1: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Retatrutide: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)
Oct 30, 2026
Viking Therapeutics Stock: What Investors Need to Know
The Motley Fool · The Motley Fool (AI Health Portfolio)